SCLERO.ORG is retiring 4-24-2021. Thank you for the memories! You'll still find us in the Wayback Machine, and we'll carry your stories in our hearts forever.
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Autoimmune Archive
We maintain news archives for the most recent 3 years.
2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021 - 2020 - 2019 - 2018

November 2020 Autoimmune News

Risk of venous thromboembolism (VTE) in rheumatoid arthritis (RA), and its association with disease activity: a nationwide cohort study from Sweden. This study demonstrates a strong association between clinical RA disease activity measured by Disease Activity Score 28 erythrocyte sedimentation rate and the risk of VTE. PubMed, Ann Rheum Dis, 10/08/2020. (Also see Symptoms and Complications of Rheumatoid Arthritis)

Interleukin-17A biomarker as a predictor for detection of early axial spondyloarthritis (SpA) changes in patients with psoriasis. Our study can imply that IL-17A is a valuable, useful and low–cost biomarker in detecting early axial SpA changes in asymptomatic and nonradiographic axial SpA psoriatic patients. PubMed, Int J Rheum Dis, 10/05/2020. (Also see Interleukins and Psoriasis and Psoriatic Arthritis)

Blood–brain barrier (BBB) leakage in systemic lupus erythematosus (SLE) is associated with gray matter loss and cognitive impairment. Our findings provide evidence for a link between extensive BBB leakage and changes in both brain structure and cognitive function in patients with SLE. PubMed, Ann Rheum Dis, 10/01/2020. (Also see Symptoms and Complications of Lupus)

Prevalence of antimitochondrial antibodies in subacute cutaneous lupus erythematosus (SCLE). A high prevalence of AMA-M2 was found in patients with SCLE. PubMed, Int J Dermatol, 10/05/2020. (Also see Antibodies in Lupus)

Residual Disease Activity (RDA) and Associated Factors in Psoriatic Arthritis (PsA). RDA can be recognized in patients with PsA and very low disease activity seems to be the most stringent composite index to identify patients in the absence of RDA. PubMed, J Rheumatol, 2020 Oct 1;47(10):1490-1495. (Also see Psoriasis and Psoriatic Arthritis)

Rheumatoid arthritis–related lung disease detected on clinical chest computed tomography imaging: Prevalence, risk factors, and impact on mortality. RA–related lung disease was commonly detected on chest CT imaging regardless of RA serostatus. Seminars in Arthritis and Rheumatism, 09/28/2020. (Also see Symptoms and Complications of Rheumatoid Arthritis)

Use and Reporting of Outcome Measures in Randomized Trials for Anti–Neutrophil Cytoplasmic Antibody–Associated Vasculitis (AAV): A Systematic Literature Review of Randomized Trials. Outcome measures used in AAV trials commonly included vasculitis–specific tools for disease assessment, but with heterogeneity in endpoint–definitions and timing of assessments. Seminars in Arthritis and Rheumatism, 09/29/2020. (Also see Vasculitis)

Case Report: Severe hypophosphataemia following oral bisphosphonate treatment in a patient with osteoporosis. Phosphate levels were quickly restored each time on replacement therapy and the case was interpreted as bisphosphonate–induced severe hypophosphataemia. PubMed, BMJ Case Rep, 2020 Oct 8;13(10):e235083. (Also see Osteoporosis)

Investigation of genetically regulated gene expression and response to treatment in rheumatoid arthritis highlights an association between IL18RAP expression and treatment response. Our results suggest that IL18RAP expression is worthy of further investigation as a potential predictor of treatment response in rheumatoid arthritis. PubMed, Ann Rheum Dis, 2020 Nov;79(11):1446-1452. (Also see Treatments for Rheumatoid Arthritis and Interleukins)

Salivary gland epithelial cells (SGECs) from patients with Sjögren's syndrome (pSS) induce B-lymphocyte survival and activation. SGECs from patients with pSS had better ability than those from controls to induce survival and activation of B lymphocytes. PubMed, Ann Rheum Dis, 2020 Nov;79(11):1468-1477. (Also see Sjögren's Syndrome Research and B Cells and T Cells)

Go to Autoimmune News: October 2020

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected]. Disclaimer. Privacy Policy.